评 Abbas 等人的研究：nusinersen 治疗脊髓性肌萎缩症的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年， ，213 页。
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213.
机构信息
Neuroscience Department, Medical Research Group of Egypt, Zagazig 44523, Egypt.
Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
出版信息
Medicina (Kaunas). 2022 Jun 6;58(6):766. doi: 10.3390/medicina58060766.
Abstract
We read with interest the article by Abbas et al. [...].
摘要
我们饶有兴趣地阅读了 Abbas 等人的文章。[...]。
相似文献
1
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213.评 Abbas 等人的研究：nusinersen 治疗脊髓性肌萎缩症的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年， ，213 页。
Medicina (Kaunas). 2022 Jun 6;58(6):766. doi: 10.3390/medicina58060766.
2
Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213".回复 Aljabali 等人对“阿巴斯等人研究的评论：nusinersen 在治疗脊髓性肌萎缩症中的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年，，213”
Medicina (Kaunas). 2022 Jun 13;58(6):793. doi: 10.3390/medicina58060793.
3
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.《依库珠单抗治疗视神经脊髓炎谱系疾病的有效性和安全性的 Meta 分析》
Medicina (Kaunas). 2022 Feb 1;58(2):213. doi: 10.3390/medicina58020213.
4
Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.目前使用 nusinersen 治疗脊髓性肌萎缩症的证据：系统评价。
Acta Neurol Belg. 2019 Dec;119(4):523-533. doi: 10.1007/s13760-019-01199-z. Epub 2019 Aug 6.
5
Nusinersen: A Treatment for Spinal Muscular Atrophy.依库珠单抗：治疗脊髓性肌萎缩症的一种方法。
Ann Pharmacother. 2019 Jan;53(1):61-69. doi: 10.1177/1060028018789956. Epub 2018 Jul 16.
6
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.七项临床试验中接受 nusinersen 治疗的有症状脊髓性肌萎缩症（SMA）婴儿和儿童的综合安全性分析。
CNS Drugs. 2019 Sep;33(9):919-932. doi: 10.1007/s40263-019-00656-w.
7
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.用nusinersen 治疗婴儿型脊肌萎缩症：2 期、开放标签、多中心、剂量递增研究的最终报告。
Lancet Child Adolesc Health. 2021 Jul;5(7):491-500. doi: 10.1016/S2352-4642(21)00100-0. Epub 2021 Jun 3.
8
The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.脊髓性肌萎缩症的隧道尽头之光变得鲜明：一篇社论亮点，内容为“用诺西那生钠治疗脊髓性肌萎缩症患者的脑脊液蛋白质组学分析”，刊登在第 650 页。
J Neurochem. 2020 Jun;153(5):545-548. doi: 10.1111/jnc.14976. Epub 2020 Mar 3.
9
Nusinersen (Spinraza) for spinal muscular atrophy.用于脊髓性肌萎缩症的诺西那生（Spinraza）
Med Lett Drugs Ther. 2017 Mar 27;59(1517):50-52.
10
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.脊髓性肌萎缩症患儿鞘内注射：诺西那生临床试验经验
J Child Neurol. 2016 Jun;31(7):899-906. doi: 10.1177/0883073815627882. Epub 2016 Jan 27.
引用本文的文献
1
Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213".回复 Aljabali 等人对“阿巴斯等人研究的评论：nusinersen 在治疗脊髓性肌萎缩症中的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年，，213”
Medicina (Kaunas). 2022 Jun 13;58(6):793. doi: 10.3390/medicina58060793.
本文引用的文献
1
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.《依库珠单抗治疗视神经脊髓炎谱系疾病的有效性和安全性的 Meta 分析》
Medicina (Kaunas). 2022 Feb 1;58(2):213. doi: 10.3390/medicina58020213.
2
How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.与其他治疗1-3型脊髓性肌萎缩症的方法相比，利司扑兰的效果如何：一项系统文献综述和间接治疗比较
J Comp Eff Res. 2022 Apr;11(5):347-370. doi: 10.2217/cer-2021-0216. Epub 2022 Jan 18.
3
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.依洛硫酸酯酶 n 注射液治疗携带 2 个 SMN2 拷贝的脊髓性肌萎缩症婴儿起病型患者的症状：一项开放标签、单臂、多中心、3 期临床试验。
Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17.
4
Risdiplam in Type 1 Spinal Muscular Atrophy.利司扑兰治疗 1 型脊髓性肌萎缩症。
N Engl J Med. 2021 Mar 11;384(10):915-923. doi: 10.1056/NEJMoa2009965. Epub 2021 Feb 24.
5
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.依库珠单抗治疗脊髓性肌萎缩症的安全性和有效性：EMBRACE 研究。
Muscle Nerve. 2021 May;63(5):668-677. doi: 10.1002/mus.27187. Epub 2021 Feb 16.
6
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察：一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
7
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
Zotero 插件